Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2013 1
2016 5
2017 1
2018 4
2019 1
2020 4
2021 4
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of anti-HER2 therapies for cancer treatment.
Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Parakh S, et al. Among authors: burvenich ijg. Cancer Treat Rev. 2017 Sep;59:1-21. doi: 10.1016/j.ctrv.2017.06.005. Epub 2017 Jul 6. Cancer Treat Rev. 2017. PMID: 28715775 Review.
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Centenera MM, et al. Among authors: burvenich ijg. Cancer Res. 2021 Apr 1;81(7):1704-1718. doi: 10.1158/0008-5472.CAN-20-2511. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547161
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM, Helm M, Shrestha RK, Moldovan M, Don AS, Holst J, Scott AM, Horvath LG, Lynn DJ, Selth LA, Hoy AJ, Swinnen JV, Butler LM. Nassar ZD, et al. Among authors: burvenich ij. Elife. 2020 Jul 20;9:e54166. doi: 10.7554/eLife.54166. Elife. 2020. PMID: 32686647 Free PMC article.
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.
Wichmann CW, Burvenich IJG, Guo N, Rigopoulos A, McDonald A, Cao D, O'Keefe GJ, Gong SJ, Gan HK, Scott FE, Pore N, Coats S, Scott AM. Wichmann CW, et al. Among authors: burvenich ijg. Nucl Med Biol. 2023 Jul-Aug;122-123:108366. doi: 10.1016/j.nucmedbio.2023.108366. Epub 2023 Jul 14. Nucl Med Biol. 2023. PMID: 37473513
Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy.
Cao Z, Burvenich IJ, Zhao K, Senko C, Glab J, Fogliaro R, Liu Z, Jose I, Puthalakath H, Hoogenraad NJ, Osellame LD, Scott AM. Cao Z, et al. Among authors: burvenich ij. Cancers (Basel). 2022 Nov 10;14(22):5533. doi: 10.3390/cancers14225533. Cancers (Basel). 2022. PMID: 36428623 Free PMC article.
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, Blyth B, Van Zuylekom J, Rigopoulos A, Burvenich IJG, Morandeau L, Mohamed S, Nowak AK, Hegi-Johnson F, MacManus M, Scott AM. Wichmann CW, et al. Among authors: burvenich ijg. Nucl Med Biol. 2023 May-Jun;120-121:108351. doi: 10.1016/j.nucmedbio.2023.108351. Epub 2023 May 16. Nucl Med Biol. 2023. PMID: 37224789 Free article.
26 results